SCHEMBL3598462

SCHEMBL3598462

C[C@@H](COCc1ccccc1)Oc1cc(Oc2ccc(S(C)(=O)=O)cc2)cc(C(=O)O)c1

nearest known ligand 0.55

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GCK P35557 19/20 0.55
KCNH2 Q12809 3/20 0.49
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664229 0.93 GCK (0.50) GCKKCNH2
SCHEMBL9071277 0.92 GCK (0.56) GCKKCNH2
SCHEMBL2664227 0.91 GCK (0.53) GCKKCNH2
SCHEMBL9987460 0.89 GCK (0.47) GCKKCNH2
SCHEMBL9987461 0.89 GCK (0.47) GCKKCNH2
SCHEMBL9986858 0.88 GCK (0.45) GCKKCNH2
SCHEMBL3595253 0.88 GCK (0.45) GCKKCNH2
SCHEMBL12070254 0.88 GCK (0.44) GCKKCNH2MEN1KMT2A
SCHEMBL1528218 0.85 GCK (0.71) GCKKCNH2
SCHEMBL1107440 0.85 GCK (0.71) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273777-B2 Glucokinase activators and methods of using same BRISTOL-MEYER SQUIBB COMPANY (US) 2012-09-25 US disclosed
US-8222285-B2 1,3-dihydroxy substituted phenylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 US disclosed
US-20100324071-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2010-12-23 US disclosed
US-20100179121-A1 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS BRISTOL-MEYERS SQUIBB COMPANY 2010-07-15 US disclosed
US-7700640-B2 Process for making phenoxy benzamide compounds ASTRAZENECA AB (SE) 2010-04-20 US disclosed
US-20080200694-A1 Process for Making Phenoxy Benzamide Compounds ASTRAZENECA AB (SE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324071-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, HK1 GCK 2/4885KCNH2 413/4885MEN1 3015/4885
US-20080200694-A1 Process for Making Phenoxy Benzamide Compounds PAH, MAOB, TYR GCK 1415/4885KCNH2 189/4885MEN1 2346/4885
US-20100179121-A1 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS GCKR, GCK, NR4A3 GCK 2/4885KCNH2 709/4885MEN1 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.